Drugs / fowlpox-PSA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003871 | Sep 1999 → Jun 2002 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fowlpox-PSA | “receive four vaccinations with fowlpox-PSA (rF-PSA), three rF-PSA vaccines followed by one vaccinia-PSA (rV-PSA) vaccine, or one rV-PSA vaccine followed by three rF-PSA vaccines.” PMID 15169798 ↗ Jun 2004 |
| Known as | rF-PSA | “receive four vaccinations with fowlpox-PSA (rF-PSA), three rF-PSA vaccines followed by one vaccinia-PSA (rV-PSA) vaccine, or one rV-PSA vaccine followed by three rF-PSA vaccines.” PMID 15169798 ↗ Jun 2004 |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00003871 ↗ |
| Modality | Vaccine | “four vaccinations with fowlpox-PSA (rF-PSA)” PMID 15169798 ↗ Jun 2004 |
| Route | Intramuscular | “Patients receive intramuscular fowlpox prostate specific antigen (PSA) vaccine at weeks 0, 6, 12, and 18.” NCT00003871 ↗ |